Ozempic's Widespread Use Raises Concerns Over Health Risks and Social Impacts

The rise of GLP-1 drugs for weight loss has sparked discussions on eating disorders, accessibility, and societal pressures, as new products and trends emerge.

• GLP-1 medications like Ozempic and Wegovy, initially developed for diabetes, are increasingly used for weight loss but raise concerns about misuse and eating disorder risks.
• Experts warn that these drugs may exacerbate disordered eating behaviors and weight stigma, particularly among vulnerable groups, including college students and those with eating disorders.
• The fitness industry has introduced tailored 'GLP-1 workouts' to address muscle loss and nutritional deficits associated with these medications, emphasizing strength training and lifestyle changes.
• Upcoming pill-based versions of GLP-1 drugs, still in clinical trials, promise potentially greater weight loss and accessibility, though their long-term safety and efficacy remain unconfirmed.
• Social and cultural dynamics around GLP-1 drugs highlight stigma, secrecy, and shifting beauty standards, with significant uptake among college students and wealthier demographics.

9 Articles

Australian Broadcasting Corporation Quartz WWD Quartz ELLE ELLE ELLE Los Angeles Times ELLE